chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19 case. I woke up with mild headache and fever, cough, congestion, fatigue. I progressed during the day and called my doctor. I got PAXLOVID which I took for 5 days. Symptoms improved after about 36 hours. I did have  recurrence of symptoms 8 days after the 1st symptoms started. Symptoms were about the same the second.
Headache, Myalgia, Arthralgia, Fever, fatigue, pain at injection site Narrative:
Flu shot given high up on my shoulder.  ~36 hrs later had severe shoulder pain, limited mobility.  Increasing pain over the next week.  Inability to do normal tasks, sleep disruption.
Sore red arm at injection site, swelling, hot to touch, itch. Red spot is approximately 3.5 inches in diameter.
Lymphedema right collar; This is a spontaneous report from a contactable nurse, the patient. A 42-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 30130BA) via an unspecified route of administration in the right arm on 17Sep2021 at 16:30 (at the age of 42-years-old), as a single dose for COVID-19 immunisation. The patient had no medical history and no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient did not receive any concomitant medications. The patient previously received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0176), via an unspecified route of administration in the left arm on 16Aug2021 at 16:30 (at the age of 42-years-old) as a single dose for COVID-19 immunisation. On 18Sep2021 at 04:00, the patient experienced lymphedema right collar. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the reported event. The clinical outcome of the event lymphedema right collar was not resolved at the time of this report.
Sick with low grade fever and fatigue for 5 days. Large lump under arm receiving the injection which was sore to the touch for about 3 days.
I did not have any adverse event after the 1st dose, only with the 2nd dose. It started 2 weeks after the 2nd dose. I started to wake up at 4am and with loud pounding heart beats and my heart beating fast and unable to fall back to sleep. I did make an appointment with my cardiologist and they did an EKG, which came back normal. I just continued taking my propranolol and was instructed to increase from once a day to twice a day if needed. The increase in the dosage of propranolol did help but it has not resolve my arrythmias. I recently had a dental appointment, which was stressful for me, I had another episode at the dental appointment. From that time on, my arrythmias have been constant and increasing. I have noticed that stressful events or if I am exerting myself can exacerbate an episode. I am having arrythmias that last several days several times a month. I have noticed the frequency is increasing at the moment.
First two does he was already on oxygen support/ his O2 dropped to 85%; Fever/ fever of 101.9 for 2 days; Cold sweats; Slept for two days; This is a spontaneous report from contactable consumers (patient and patient's wife). A 50-year-old male patient received the first dose of BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE) via an unspecified route of administration on an unspecified date (batch/lot number was not reported)  at an unknown age at vaccination, as DOSE 1, SINGLE and the second dose of BNT162B2 (PFIZER BIONTECH COVID-19 VACCINE) via an unspecified route of administration, administered in the left arm on 03Sep2021 13:00 (batch/lot number: EW0198) at the age of 50 years old, as DOSE 2, SINGLE for COVID-19 immunization. The patient's medical history included high cholesterol, heart (heart disorder), and overweight, all from an unknown date. Patient had history of COVID-19 infection from an unknown date and had high heart rate since COVID-19. Patient had no known allergies. Concomitant medications in two weeks included acetylsalicylic acid (ASPIRIN) and colestyramine (COLESTROL), both taken for an unspecified indication, start and stop dates were not reported. Patient is also taking heart meds (unspecified). The patient did not receive other vaccine in four weeks. The patient is a Covid vent survivor; in the first two doses, he was already on oxygen support so, did not notice a dip. Patient also had fever and cold sweats and slept for two days after each dose. It was reported that on 04Sep2021, his O2 dropped to 85% at 04:00 am and required oxygen supplements. Patient had fever of 101.9 for 2 days. As his wife, the reporter was well versed at this point with his care of just implemented care as needed. They followed up with Dr after weekend to update. Therapeutic measures where taken as a result of the events. The patient recovered from the event "fever/ fever of 101.9 for 2 days" on 06Sep2021. Outcome of the other events was recovering. The event "first two does he was already on oxygen support/ his O2 dropped to 85%" was reported as medically significant. The patient was not tested for Covid-19 post vaccination.  The batch/lot number for BNT162B2 (first dose) was not provided and will be requested during follow-up.
to ER for rt ankle & rt leg pain, bruising on rt lateral thigh; to ER 5JUL dx HSP; seen in ofc w/hematuria 31JUL95
Patient had received PEDIARIX in past so was going to get KINRIX. I saw it on the box Dtap and IPV, then I saw it on the bottle, but in my head it was registering as the Dtap being the same brand and that he still needed the IPV. Afterwards when we were doing our after checks it was picked up by the other nurse.
No additional AE or PQC reported.; VARIVAX was administered after a temperature excursion.; This spontaneous report was received from a nurse and referred to a patient of unknown age and gender. The patient's medical history, concurrent conditions, concomitant therapies, drug reactions and allergies were not reported.  On 02-FEB-2023, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) subcutaneous injection, 0.5 milliliter(ml), lot #W012165, expiration date: 12-APR-2024, administered for prophylaxis (strength and route of administration were not provided). The administered varicella virus vaccine live (oka/merck) (VARIVAX) had a previous temperature excursion of minus 11.9 degree Celsus (C) for unknown time frame (product storage error). No additional adverse event (AE) was reported.
Left arm and left foot numb/tingly since vaccine. Still numb/tingly 10 days later.  Left shoulder and neck sore. Dizziness, nausea, headaches, forgetfulness, inability to complete thoughts/finish sentences. Trouble focusing.  Brain fogginess/forgetfulness/inability to finish thoughts and headaches still happening 10 days later.
Patient started to have muscle twitching of deltoid vaccine administered (left deltoid) occurred approximately 1 week following vaccination and lasted for a duration of 1 week. Mild sore arm day following vaccination with no other symptoms.
Information has been received from a physician and a nurse manager concerning a female child who in approximately March 2007, was vaccinated with a dose of Zostavax (lot # 656394/0162U) instead of a dose of Varivax. Unspecified medical attention was sought. A product quality complaint was not involved. The nurse reported that the shipment of Zostavax normally comes in a box that is labeled for another department in their building called "adult medicine." This shipment of Zostavax came in a box labeled "pediatrics" and therefore, came to the nurse's department. It was assumed that this was their normal shipment of Varivax and was therefore dispensed to the patient. She noted that they would be following the normal Varivax schedule and the patient would be given the scheduled booster dose. This is one of several reports received from the same source. Additional information has been requested
This spontaneous report as received from a physician refers to a patient of unknown age and gender. The patient's concomitant medications, pertinent medical history, and drug reactions and allergies were not provided.  On an unspecified date, the patient received an improperly stored dose of vaccinated with M-M-R II, (dose, frequency, and route were not provided), (lot # was reported as M034856, with an expiration date of 27-JUL-2018) for prophylaxis. Other suspect therapies included sterile diluent(STERILE DILUENT) used to reconstitute the dose of M-M-R II, (lot # and expiration date were not provided).  The physician reported that the dose of M-M-R II, may have been exposed to light due to "the M-M-R II was stored in the refrigerator without the lid on the box". No adverse effect reported. Product quality compliant was not involved. No additional information was provided. Additional information has been requested.
This spontaneous report as received from the patient's mother refer to her 2 month old son. On an unknown date, the patient was vaccinated (route not provided) with PNEUMOVAX 23 (lot number and expiry date not provided). On an unknown date, the reporter's 2 month old son received PNEUMOVAX and was suffering from low grade fever. It was confirmed with patient's mother that the age of her son was 2 months old and he received PNEUMOVAX 23. The outcome of low grade fever and 2 month old son received PNEUMOVAX was unknown. The reporter did not assess the relationship between the low grade fever and PNEUMOVAX 23. Additional information is not expected.
pt recvd vax; mom notified ofc 13dec94 in am, reporting that pt had uncontrolable crying spell since vax;12dec at 5pm reported a low grade fever;tx w/ apap;attack subsided w/in next 4 hrs; fully recovered;
shortness of breath; congestion/congestive heart failure; frequent falls; failure to thrive; pneumonia; severe cardiomyopathy; pleural effusions secondary to congestive heart failure; died; This initial spontaneous information was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age.  On or about 02-OCT-2017, the patient was inoculated with zoster vaccine live (ZOSTAVAX) for routine health maintenance and for its intended purpose: the prevention of shingles (herpes zoster). Shortly after, the patient suffered shortness of breath, congestion, frequent falls and failure to thrive requiring hospitalization. The patient was diagnosed with congestive heart failure, pleural effusions secondary to congestive heart failure, pneumonia and severe cardiomyopathy. As a direct and proximate result of these injuries, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient suffered significant medical expenses, severe pain and suffering, other damages, and ultimately death on 06-MAR-2018. As a direct and proximate result of zoster vaccine live (ZOSTAVAX), the patient suffered serious and dangerous side effects, including death, as well as other severe and personal injuries which are permanent and lasting in nature, physical pain and mental anguish, emotional distress, loss of enjoyment of life, physical impairment and injury. As a direct and proximate result of Company's conduct, the patient has suffered and incurred damages, including medical expenses; the loss of accumulations; and other economic and non-economic damages.  The outcome of the events was considered to be not recovered. All of the events were considered to be related to zoster vaccine live (ZOSTAVAX).  Upon internal review, the events of cardiomyopathy, pneumonia, failure to thrive and congestive heart failure were considered to be medically significant. The events of congestive heart failure, pleural effusions secondary to congestive heart failure, pneumonia, severe cardiomyopathy, shortness of breath, congestion, frequent falls and failure to thrive were considered to be disabling.
Myalgia of left shoulder/trapezius area. Myalgia still noted today (12/6/13), although getting better.
On 10/15/2021 that night I started feeling feverish, very weak, muscle ache. Temp was 103 at the high side. I took three Motrin's and went to bed. On 10/16/2021 I woke up very sore and fatigued, so I rested and took more Motrin, no fever. On 10/17/2021 I was well besides a bit of swelling at the injection site and bit bruised.
Employee had headache, cramps in legs, stiffness in entire body, diarrhea and vomiting about 6 hrs after shot given.
Systemic: Confusion-Medium, Systemic: Fainting / Unresponsive-Severe, Systemic: Shakiness-Medium, Additional Details: Fainted within 15 minutes of vaccination in Aisle 9
6 days p/DT vax pt began to exp diffuse erythema @ inject site, measuring, 55mmx42mm & induration; No pruritus or constitutional sx; tx APAP-limited use rt arm, ice; t99.5; BP 102/62, P84;
BRIEF OVERVIEW: Admission Date: 9/8/2023 Discharge Date: 9/15/2023 Discharge Disposition:  home health care svc    DETAILS OF HOSPITAL STAY: PRESENTING PROBLEM: Hyponatremia [E87.1] Weakness [R53.1] Pneumonia due to COVID-19 virus [U07.1, J12.82]   HOSPITAL COURSE: Patient is a 67 year old female with history of bipolar on ECT who presented on 9/8 with left sided weakness and facial droop and a fall at home. She was admitted for a stroke work up. EEG and MRI were unremarkable and thus stroke was ruled out. Shortly after admission, she had declining respiratory status and was found to be positive for COVID. Oxygen requirements escalated to 60% FiO2 on 40 L high flow oxygen so she was started on Decadron and Remdesivir. Over the ensuing days, patient was slowly weaned off of oxygen and was back to room air by 9/11. She completed 5 days of Remdesivir and was scheduled for a 10 day course of Decadron which was converted to oral for outpatient completion. Patient also had an acute on chronic hyponatremia that was attributed to her ECT and this resolved during her stay with fluid restrictions. Patient was evaluated by PT and OT and originally recommended inpatient rehab though with continued treatment of her COVID, she progressed to the point of recommending home health care. Patient was discharged home in stable condition on 9/15.
intermittent fevers, extreme muscle ache, Left axillary lymphadenopathy for over 24 hours. Took ibuprofen and tylenol which exacerbated stomach ache.  Then took sucralfate and esomeprazole and tylenol supp.
Mild rashes at injection site in shoulder\ Mild rashes in torso\  Mild rashes in arms\Mild rashes in upper legs; . This case was reported by a nurse via call center representative and described the occurrence of rash in a elderly male patient who received Herpes zoster (Shingrix) (batch number 72F23, expiry date 31st March 2021) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were reported as follows: The age at vaccination was not reported. The patient experienced mild rashes at injection site after 1st dose of Shingrix. She also specified that the rashes went from shoulder, arms, torso and upper legs. The healthcare professional (HCP) was not sure if it was the first dose. The reporter consented to follow up. This case has been linked with the case US2020042788, reported by the same reporter.
Three (3) inch erythema below the injection site, hot to touch and very tender the first 24 - 48 hours.
About 20 minutes after receiving vaccine I felt a very hot area in the center lower part of my chest. It radiate it out and up into my throat. It only lasted a few minutes and completely went away. About seven hours later the same thing happened but the heat was not intense as it was the first time. Nail two days later, I have a slight, very slight feeling of heat in my lower throat. I?ve never had any of these symptoms before.
Patient brought to the emergency department by EMS for weakness on 6/6. COVID-19 PCR testing was positive on that day (6/6), however patient had a previous positive test on 5/20. The patient was admitted from 6/6-6/8. This meets criteria for vaccine breakthrough case review.
small amount of vaccine material came out onto her arm; This spontaneous case was reported by a health care professional and describes the occurrence of ACCIDENTAL UNDERDOSE (small amount of vaccine material came out onto her arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     No Medical History information was reported.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to dosage form. On an unknown date, the patient experienced ACCIDENTAL UNDERDOSE (small amount of vaccine material came out onto her arm). At the time of the report, ACCIDENTAL UNDERDOSE (small amount of vaccine material came out onto her arm) had resolved. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   The patient is asking the physician if she needs to get the dose repeated or not. Offered the physician information in writing, but he declined. Ok for the safety team to reach out to the physician later if needed
pt recv vax 17DEC96 & pt devel red blotches on back & abd that were itchy;18DEC96 pt visited a MD office in the morning @ which time the red spots were still there , but had dec in size;
Pulmonary Distress Hypoxia; Viral pneumonia; Hypoxia; Inflammation; Fatigue; Headache; This spontaneous case was reported by a consumer and describes the occurrence of ACUTE RESPIRATORY DISTRESS SYNDROME (Pulmonary Distress Hypoxia), PNEUMONIA VIRAL (Viral pneumonia) and HYPOXIA (Hypoxia) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes and Left anterior descending coronary artery stenosis.    On 01-Aug-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ACUTE RESPIRATORY DISTRESS SYNDROME (Pulmonary Distress Hypoxia) (seriousness criteria hospitalization and medically significant), PNEUMONIA VIRAL (Viral pneumonia) (seriousness criteria hospitalization and medically significant), HYPOXIA (Hypoxia) (seriousness criteria hospitalization and medically significant), INFLAMMATION (Inflammation), FATIGUE (Fatigue) and HEADACHE (Headache). The patient was hospitalized on 02-Aug-2021 due to HYPOXIA and PNEUMONIA VIRAL. The patient was treated with REMDESIVIR for COVID-19, at an unspecified dose and frequency. At the time of the report, ACUTE RESPIRATORY DISTRESS SYNDROME (Pulmonary Distress Hypoxia), PNEUMONIA VIRAL (Viral pneumonia) and HYPOXIA (Hypoxia) had resolved and INFLAMMATION (Inflammation), FATIGUE (Fatigue) and HEADACHE (Headache) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Oxygen saturation: 80% (Low) 80%.         The concomitant medication were not provided.  The patient was in floor Isolation then ICU for heart and oxygen levels.On August second, the patient was the only Vaccinated patient to be Hospitalized for positive tested where the Delta was active.  Company Comment :This case concerns a patient with unknown age and gender with past medical history Diabetes Mellitus and Left anterior descending coronary artery stenosis, who had adverse events of Acute Respiratory Distress Syndrome, Pneumonia Viral, Hypoxia, Inflammation, Fatigue, Headache, and was subsequently hospitalized approximately after 4 months of receiving the 2nd dose of the vaccine. Very limited information regarding this events has been provided at this time. Further information has been requested.; Sender's Comments: This case concerns a patient with unknown age and gender with past medical history Diabetes Mellitus and Left anterior descending coronary artery stenosis, who had adverse events of Acute Respiratory Distress Syndrome, Pneumonia Viral, Hypoxia, Inflammation, Fatigue, Headache, and was subsequently hospitalized approximately after 4 months of receiving the 2nd dose of the vaccine. Very limited information regarding this events has been provided at this time. Further information has been requested.
Severe itching rash started with legs and moved  to upper body.  Full body looks like measles, at 10 weeks without much regression.  PCP tried Prednisone(ramped up to 60mg) at my request from previous eczema outbreaks.  Predinsone had little effect until hitting 60mg, triamcinolone cream with daily showers seems to be best but the itching puts me backwards to recovery or hard to fully heal.
She reported fever of 99 (97 normal) and a headache, woke up at 2:00 am felt sick arm swollen and sore and had a headache
Male Patient oriented in space and time at 6 minutes after the moderna vaccine second dose, report to feel dizziness, sweating and pale skin. At this moment we take the vitals; SO2% 98, 81 HR.  After evaluation patient report to feel better and take water.
Information has been received from a registered nurse concerning an 8 year old female who on 02/28/1997 was vaccinated with a first dose of varicella vaccine SC in the left arm and a second dose of MMR SC in the right arm.  On 10/17/2001, the pt presented with chicken pox at the physician's office. The pt broke out in an itchy rash with "numerous raised 1/2 to 1 cm lesions with a red border and clear center." The pt had rash on her face, scalp, and trunk. The nurse reported that the pt did not have a fever at the office but the pt's mother stated that she had a fever at home. The fever and itchy, vesicular rash continued to develop over the course of several days. The pt subsequently recovered. No additional info is expected.
Fri, Apr 30, 8:53 PM (2 days ago)  to vaers  On April 7th, I took vaccine #1 at pharmacy. Within in an hour I got a reaction similar to what I got from sulfur type antibiotics including:  Facial swelling, difficulty swallowing and numbness of face, lips, tongue, teeth.  I am assuming that there is sulfur in Pfizer. Others should be aware of this.  If you have any questions, call me
This case was reported by a pharmacist via call center representative and described the occurrence of chills in a 51-year-old female patient who received SHINGRIX (batch number 3Z4KL, expiry date 30th January 2010) and (batch number 5942P ?, expiry date unknown). Concurrent medical conditions included hypothyroidism. On 2nd February 2018 12:00, the patient received the 1st dose of SHINGRIX (intramuscular). On an  unknown date, the dose was an unknown dose. On 2nd February 2018 06:00, 6 hrs after receiving SHINGRIX, the patient experienced chills and pain in extremity. On 2nd February 2018, the outcome of the chills and pain in extremity were recovered/resolved. The reporter considered the chills and pain in extremity to be almost certainly related to SHINGRIX. Additional details were provided as follows: The patient received SHINGRIX on left deltoid. The patient had shivering, chills, shooting pain in foot and leg all occurred at the same time and patient was in bed for 36 hours post vaccine administration. The vaccine was given at 12 pm and the side effects happened 6 hours after administration at 6 pm. The reported Adjuvant Lot number 942P did not match with any GlaxoSmithKline lot number. Clarification has been requested. The SHINGRIX lot number and expiration date was listed above in the form.